Teva Pharmaceutical Industries Ltd. and Active Biotech introduced the publications of outcome that came from the laquinimod Phase III ALLEGRO study within the March 15 issues of The New England Journal of Medicine. Statistics coming from the two year study confirmed that in fact oral once-daily laquinimod decreased inflammatory disorder exercise as measured by medical relapses and Magnetic Resonance Imaging (MRI), slowed disability progression and diminished brain tissue loss, while maintaining a positive safety and tolerability profile in affected individuals along with relapsing-remitting multiple sclerosis (RRMS).
"The constructive revelation from ALLEGRO provided facts, which experts state laquinimod represents an exclusive method in the treatment of multiple sclerosis, one that offers relapse administration accompanied by a significant lowering of the key outcome measures interconnected to irreversible nervous cells destruction," said Giancarlo Comi.
The ALLEGRO outcome, in addition to results coming from the second global Phase III evaluation of laquinimod, BRAVO, will probably be covered in the application for regulatory approval deliberate for distribution into the European Medicines Agency (EMA) within the second half of this year.
"The journal of typical ALLEGRO results in a reputable peer-reviewed journal is a vital landmark when we continue to research and build laquinimod," said Lesley Russell, Senior Vice President of R&D, Teva Global Branded Products. "We examine forward to carrying on with to work with regulatory authorities in each of the EU and the U.S. to bring this approach novel therapy towards the MS community."
No comments:
Post a Comment